Sangamo Therapeutics Competitors

Amgen (NASDAQ:AMGN) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Amgen and Sangamo Therapeutics' revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Sangamo Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amgen and Sangamo Therapeutics, as provided by MarketBeat.com.

Amgen presently has a consensus price target of $261.0476, indicating a potential upside of 1.67%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Amgen.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Amgen beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Gilead Sciences and Sangamo Therapeutics' revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Sangamo Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gilead Sciences and Sangamo Therapeutics, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $97.92, indicating a potential upside of 46.43%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Gilead Sciences.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Summary

Gilead Sciences beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vertex Pharmaceuticals and Sangamo Therapeutics, as provided by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus price target of $293.1250, indicating a potential upside of 32.98%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 75.96%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Vertex Pharmaceuticals.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Sangamo Therapeutics' revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Sangamo Therapeutics on 11 of the 15 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Regeneron Pharmaceuticals has a consensus price target of $646.2609, indicating a potential upside of 28.58%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Regeneron Pharmaceuticals.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Sangamo Therapeutics on 12 of the 15 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Biogen, as reported by MarketBeat.

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Biogen has a consensus price target of $303.5862, indicating a potential upside of 12.12%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Biogen.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Biogen's revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Sangamo Therapeutics on 9 of the 14 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Sangamo Therapeutics and Alexion Pharmaceuticals, as reported by MarketBeat.

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 75.96%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 6.00%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Alexion Pharmaceuticals.

Insider and Institutional Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Sangamo Therapeutics and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sangamo Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Sangamo Therapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Sangamo Therapeutics on 11 of the 15 factors compared between the two stocks.